Agilent Technologies (NYSE:A) Releases FY 2026 Earnings Guidance

Agilent Technologies (NYSE:A) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 6.180-6.210 for the period, compared to the consensus EPS estimate of 6.060. The company issued revenue guidance of $7.5 billion-$7.5 billion, compared to the consensus revenue estimate of $7.4 billion. Agilent Technologies also updated its Q4 2026 guidance to 1.710-1.740 EPS.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Weiss Ratings raised Agilent Technologies from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, June 2nd. Morgan Stanley lifted their price objective on shares of Agilent Technologies from $160.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Wolfe Research reaffirmed a “hold” rating on shares of Agilent Technologies in a report on Tuesday, June 2nd. Stifel Nicolaus increased their target price on shares of Agilent Technologies from $170.00 to $180.00 and gave the company a “buy” rating in a research report on Thursday. Finally, HSBC lowered their target price on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Agilent Technologies has an average rating of “Moderate Buy” and a consensus target price of $170.33.

Agilent Technologies Price Performance

NYSE A opened at $157.60 on Friday. The stock has a market capitalization of $44.51 billion, a P/E ratio of 31.02, a P/E/G ratio of 2.74 and a beta of 1.25. Agilent Technologies has a 1 year low of $108.35 and a 1 year high of $163.75. The business’s fifty day moving average is $139.76 and its two-hundred day moving average is $126.85. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.13. The company had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.84 billion. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.84%. The company’s revenue was up 8.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, research analysts forecast that Agilent Technologies will post 6.05 earnings per share for the current fiscal year.

Key Headlines Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent exceeded quarterly expectations. Fiscal Q3 revenue rose 8.1% year over year to $1.88 billion, above the $1.84 billion consensus estimate. Non-GAAP EPS was $1.62, ahead of the $1.49 estimate and up from $1.37 a year earlier. GAAP net income reached $362 million, or $1.28 per share. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: Management raised its fiscal 2026 outlook. Full-year adjusted EPS guidance increased to $6.18-$6.21, above the $6.06 analyst consensus, while revenue guidance of approximately $7.5 billion also exceeded expectations. Fourth-quarter EPS guidance of $1.71-$1.74 was at or above consensus. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Growth and operating leverage are improving. Operating profit rose 23.3% to $444 million, while operating cash flow increased 43.4% to $519 million. Commentary highlighted product momentum, recovering Chinese demand and margin expansion as drivers of the stronger performance. A Q2 Deep Dive: Product Momentum, China Recovery, and Operating Leverage Drive Results
• Positive Sentiment: Analyst sentiment strengthened materially. Citigroup, JPMorgan, RBC, Stifel, Bank of America, Goldman Sachs, Barclays, TD Cowen and Bernstein all raised price targets, with new targets generally ranging from $175 to $190 and buy, overweight or outperform ratings. Analyst price-target updates
• Neutral Sentiment: At roughly 31 times earnings and near its 52-week high, Agilent’s valuation already reflects considerable optimism. Sustaining the rally will likely depend on continued demand recovery and delivery of the raised guidance.

Institutional Investors Weigh In On Agilent Technologies

Several hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its position in shares of Agilent Technologies by 1.9% during the 4th quarter. State Street Corp now owns 12,681,792 shares of the medical research company’s stock valued at $1,725,611,000 after acquiring an additional 241,029 shares in the last quarter. Morgan Stanley grew its stake in shares of Agilent Technologies by 15.9% in the 4th quarter. Morgan Stanley now owns 5,041,881 shares of the medical research company’s stock valued at $686,049,000 after purchasing an additional 692,202 shares during the period. Invesco Ltd. raised its holdings in shares of Agilent Technologies by 32.0% in the 4th quarter. Invesco Ltd. now owns 2,590,715 shares of the medical research company’s stock worth $352,519,000 after buying an additional 627,804 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Agilent Technologies by 132.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company’s stock worth $277,807,000 after buying an additional 1,340,161 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Agilent Technologies by 424.1% in the 2nd quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock worth $240,956,000 after buying an additional 1,652,244 shares in the last quarter.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.